249 related articles for article (PubMed ID: 1965878)
1. The hybridization of EBV-immortalized human B-lymphocytes with a human-mouse heteromyeloma cell line.
Jahn S; Walper A; Grunow R; Heym S; Volk HD; von Baehr R
Allerg Immunol (Leipz); 1990; 36(4):359-65. PubMed ID: 1965878
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibody to purified protein derivative of tuberculin produced by hybrids constructed with Epstein-Barr virus-transformed B lymphocytes and mouse myeloma cells.
Garzelli C; Puglisi C; Falcone G
Eur J Immunol; 1986 May; 16(5):584-7. PubMed ID: 3009205
[TBL] [Abstract][Full Text] [Related]
3. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
4. Relationship between immunoglobulin production and immortalization by Epstein Barr virus.
Tosato G; Blaese RM; Yarchoan R
J Immunol; 1985 Aug; 135(2):959-64. PubMed ID: 2989369
[TBL] [Abstract][Full Text] [Related]
5. Human T cell hybridomas specific for Epstein Barr virus-infected B lymphocytes.
Lakow E; Tsoukas CD; Vaughan JH; Altman A; Carson DA
J Immunol; 1983 Jan; 130(1):169-72. PubMed ID: 6292301
[TBL] [Abstract][Full Text] [Related]
6. Changes in the phenotype and immunoglobulin secretion of human B cells following co-culture with cells of an EBV+ lymphoblastoid line or fusion with mouse plasmacytoma cells. Studies in short-term and long-term culture.
Ling NR; Lowe JA
Clin Exp Immunol; 1989 Feb; 75(2):311-6. PubMed ID: 2539279
[TBL] [Abstract][Full Text] [Related]
7. Generation of human anti-rubella monoclonal antibodies from human hybridomas constructed with antigen-specific Epstein-Barr virus transformed cell lines.
Hilfenhaus J; Kanzy EJ; Köhler R; Willems WR
Behring Inst Mitt; 1986 Jun; (80):31-41. PubMed ID: 3019293
[TBL] [Abstract][Full Text] [Related]
8. SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus.
Gustafsson B; Jondal M; Sundqvist VA
Hum Antibodies Hybridomas; 1991 Jan; 2(1):26-32. PubMed ID: 1651784
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus.
Brown NA; Miller G
J Immunol; 1982 Jan; 128(1):24-9. PubMed ID: 6274955
[TBL] [Abstract][Full Text] [Related]
10. Renewal of EBV-hybridoma method: efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells.
Ainai A; Kawase T; Ida A; Maeda Y; Ohba H; Ikeda Y; Sato H; Takahashi M; Chiba J
Hum Antibodies; 2006; 15(4):139-54. PubMed ID: 17522436
[TBL] [Abstract][Full Text] [Related]
11. Characterization of stable Epstein-Barr (EB) virus transformed cell lines and mouse-human hybridomas producing a large quantity of anti-tetanus toxoid (TT) monoclonal antibody.
Minakawa H; Hirata Y; Sugawara I; Fukuda A; Yoshida TO
Behring Inst Mitt; 1985 Dec; (78):139-47. PubMed ID: 3008706
[TBL] [Abstract][Full Text] [Related]
12. Establishment of specific antibody producing human lines by antigen preselection and Epstein-Barr virus (EBV)-transformation.
Steinitz M; Koskimies S; Klein G; Mäkelä O
J Clin Lab Immunol; 1979 Apr; 2(1):1-7. PubMed ID: 95800
[TBL] [Abstract][Full Text] [Related]
13. Improvement of EBV transformation and cloning efficiency of human B cells using culture supernatants from lymphoblastoid cell lines.
Mevissen ML; Kwekkeboom J; Goormachtig E; Lindhout E; de Groot C
Hum Antibodies Hybridomas; 1993 Apr; 4(2):66-73. PubMed ID: 8390865
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of EBV-transformable human B lymphocyte populations.
Chan MA; Stein LD; Dosch HM; Sigal NH
J Immunol; 1986 Jan; 136(1):106-12. PubMed ID: 2999241
[TBL] [Abstract][Full Text] [Related]
15. Human anti-cytomegalovirus (CMV) immunoglobulins secreted by EBV-transformed B-lymphocytes cell lines.
Amadei C; Michelson S; Frot JC; Fruchart MF; Nicolas H; Boué A
Dev Biol Stand; 1984; 57():283-6. PubMed ID: 6098499
[TBL] [Abstract][Full Text] [Related]
16. [Attempts to improve hybridoma technology for the production of human monoclonal antibodies].
Tokunaga T; Chiba J; Ohnishi K
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2198-204. PubMed ID: 3038035
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three human-murine heteromyeloma cell lines for formation of human hybridomas after electrofusion with human peripheral blood lymphocytes from meningococcal cases and carriers.
Delvig AA; Koumaré B; Glaser RW; Wang JF; Jahn S; Achtman M
Hum Antibodies Hybridomas; 1995; 6(2):42-6. PubMed ID: 7492749
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonals against erythrocyte antigens.
Ernst M; Sonneborn HH
Hum Antibodies Hybridomas; 1990; 1(3):122-5. PubMed ID: 1966475
[TBL] [Abstract][Full Text] [Related]
19. Antibody production of a human EBV-transformed B cell line and its heterohybridoma and trioma cell line descendants in different culture systems.
Gustafsson B; Hinkula J
Hum Antibodies Hybridomas; 1994; 5(3-4):98-104. PubMed ID: 7756584
[TBL] [Abstract][Full Text] [Related]
20. Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma.
Kozbor D; Roder JC; Chang TH; Steplewski Z; Koprowski H
Hybridoma; 1982; 1(3):323-8. PubMed ID: 6092264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
